Recent events
Recent events tied to this brand in public sources.
Back to profile5 entries
2022
Bio-Techne and Thermo Fisher agree to develop and commercialize ExoTRU
Bio-Techne announced an agreement with Thermo Fisher Scientific to exclusively complete development of and commercialize ExoTRU, a kidney transplant rejection test developed by Exosome Diagnostics, a Bio-Techne brand.
2021
Bio-Techne launches ExCellerate iPSC Expansion Medium
Bio-Techne announced the launch of ExCellerate iPSC Expansion Medium, a new medium for expanding and maintaining induced pluripotent stem cells for research and translational workflows.
2021
Bio-Techne completes acquisition of Asuragen
Bio-Techne announced that it had completed its acquisition of Asuragen. The transaction included initial consideration of $215 million in cash plus contingent consideration of up to $105 million upon achievement of certain future milestones.
2020
Bio-Techne announces B-MoGen portfolio rebrand as R&D Systems
Bio-Techne announced that the B-MoGen Biotechnologies portfolio of genome engineering services, GMP therapeutic manufacturing services and its TcBuster gene transfer system would be rebranded as R&D Systems. The B-MoGen website would be retired, with service details and purchasing options maintained on the R&D Systems website.
2020
Bio-Techne announces rebrand of Atlanta Biologicals portfolio
Bio-Techne announced that the Atlanta Biologicals serum and media portfolio would be rebranded as R&D Systems. The Atlanta Biologicals website would be retired, with portfolio information and purchasing options maintained through the R&D Systems website.